1. Home
  2. ETNB vs TIXT Comparison

ETNB vs TIXT Comparison

Compare ETNB & TIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • TIXT
  • Stock Information
  • Founded
  • ETNB 2018
  • TIXT 2005
  • Country
  • ETNB United States
  • TIXT Canada
  • Employees
  • ETNB N/A
  • TIXT N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • TIXT EDP Services
  • Sector
  • ETNB Health Care
  • TIXT Technology
  • Exchange
  • ETNB Nasdaq
  • TIXT Nasdaq
  • Market Cap
  • ETNB 1.0B
  • TIXT 1.0B
  • IPO Year
  • ETNB 2019
  • TIXT 2021
  • Fundamental
  • Price
  • ETNB $6.06
  • TIXT $2.48
  • Analyst Decision
  • ETNB Strong Buy
  • TIXT Hold
  • Analyst Count
  • ETNB 10
  • TIXT 9
  • Target Price
  • ETNB $27.56
  • TIXT $5.33
  • AVG Volume (30 Days)
  • ETNB 2.5M
  • TIXT 272.0K
  • Earning Date
  • ETNB 05-08-2025
  • TIXT 05-09-2025
  • Dividend Yield
  • ETNB N/A
  • TIXT N/A
  • EPS Growth
  • ETNB N/A
  • TIXT N/A
  • EPS
  • ETNB N/A
  • TIXT N/A
  • Revenue
  • ETNB N/A
  • TIXT $2,658,000,000.00
  • Revenue This Year
  • ETNB N/A
  • TIXT $3.72
  • Revenue Next Year
  • ETNB N/A
  • TIXT $3.63
  • P/E Ratio
  • ETNB N/A
  • TIXT N/A
  • Revenue Growth
  • ETNB N/A
  • TIXT N/A
  • 52 Week Low
  • ETNB $4.16
  • TIXT $2.13
  • 52 Week High
  • ETNB $11.84
  • TIXT $8.49
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 42.57
  • TIXT 43.03
  • Support Level
  • ETNB $5.68
  • TIXT $2.40
  • Resistance Level
  • ETNB $6.13
  • TIXT $2.50
  • Average True Range (ATR)
  • ETNB 0.69
  • TIXT 0.17
  • MACD
  • ETNB 0.03
  • TIXT 0.02
  • Stochastic Oscillator
  • ETNB 51.62
  • TIXT 55.12

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares

TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.

Share on Social Networks: